- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01641133
Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™
February 8, 2021 updated by: GlaxoSmithKline
Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™
The primary aim of this study is to assess the reactogenicity of Synflorix vaccine and Prevenar 13 vaccine after primary vaccination at 2 and 4 months of age with either Synflorix or Prevenar 13 vaccine or Prevenar 13 and Synflorix, respectively.
In addition, this study aims at assessing the safety, reactogenicity, immunogenicity and antibody persistence (approximately 8-11 months following primary vaccination) of the Synflorix vaccine and Prevenar 13 vaccine after primary vaccination at 2 and 4 months of age with either Synflorix or Prevenar 13 vaccine or Prevenar 13 and Synflorix, respectively.
This study also aims at assessing the safety, reactogenicity and immunogenicity of the Synflorix vaccine when given as a booster dose at 12-15 months of age following primary vaccination at 2 and 4 months of age with either Synflorix vaccine or Prevenar 13 vaccine or Prevenar 13 and Synflorix respectively.
Study Overview
Status
Completed
Detailed Description
This study is partially blinded as the primary phase will be conducted in an observer-blind method and booster phase will be open method.
Study Type
Interventional
Enrollment (Actual)
457
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mexico, Mexico, 04530
- GSK Investigational Site
-
-
Morelos
-
Cuernavaca, Morelos, Mexico, 62210
- GSK Investigational Site
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64460
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
- A male or female between, and including, 6-12 weeks of age at the time of the first vaccination.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Born after a gestation period of at least 36 weeks.
- Written informed consent obtained from the parent(s)/LAR(s) of the subject.
Exclusion Criteria:
- Child in care.
- Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the entire study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs since birth or planned use during the study.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine.
- Major congenital defects or serious chronic illness.
- History of any seizures or progressive neurological disease.
- Administration of immunoglobulins and/or blood products since birth or planned use during the study.
- Acute disease and/or fever at the time of enrolment.
- Previous vaccination or planned vaccination during the study with any pneumococcal vaccine.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Synflorix Group
Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
|
3 doses administered intramuscularly
|
Experimental: Prevnar 1 Group
Subjects who were primed with Prevnar 13 and Synflorix vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.
|
2 doses administered intramuscularly
1 dose administered intramuscularly
|
Experimental: Prevnar 2 Group
Subjects who were primed with two doses of Prevnar 13 vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
|
1 dose administered intramuscularly
2 doses administered intramuscularly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Grade 3 Adverse Events (AEs) (Solicited and Unsolicited) - Primary Period
Time Frame: Within 31-day (Day 0-Day 30) after any dose of primary vaccination
|
The number of subjects with Grade 3 AEs (solicited and unsolicited), during the 31-day post-vaccination period following each primary dose is reported.
|
Within 31-day (Day 0-Day 30) after any dose of primary vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms - Primary Period
Time Frame: During the 4-day (Days 0-3) post-vaccination period following each primary dose
|
Solicited local symptoms assessed include pain, redness and swelling.
Grade 3 pain was defined as crying when limb was moved/spontaneously painful.
Grade 3 swelling/redness was defined as swelling/redness larger than (>) 30 millimeters (mm).
"Any" is defined as incidence of the specified symptom regardless of intensity.
|
During the 4-day (Days 0-3) post-vaccination period following each primary dose
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms - Booster Period
Time Frame: During the 4-day (Days 0-3) post-booster vaccination period
|
Solicited local symptoms assessed include pain, redness and swelling.
Grade 3 pain was defined as crying when limb was moved/spontaneously painful.
Grade 3 swelling/redness was defined as swelling/redness larger than (>) 30 millimeters (mm).
"Any" is defined as incidence of the specified symptom regardless of intensity.
|
During the 4-day (Days 0-3) post-booster vaccination period
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms - Primary Period
Time Frame: During the 4-day (Days 0-3) post-vaccination period following each primary dose
|
Solicited general symptoms assessed include drowsiness, fever (defined as axillary temperature ≥ 37.5°C), irritability, and loss of appetite.
Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities.
Grade 3 fever was defined as fever (axillary temperature) above (>) 39.5 degree Celsius (°C).
Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity.
Grade 3 loss of appetite was defined as the subject not eating at all.
"Any" is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.
|
During the 4-day (Days 0-3) post-vaccination period following each primary dose
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms - Booster Period
Time Frame: During the 4-day (Days 0-3) post-booster vaccination period
|
Solicited general symptoms assessed include drowsiness, fever (defined as axillary temperature ≥ 37.5°C), irritability, and loss of appetite.
Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities.
Grade 3 fever was defined as fever (axillary temperature) above (>) 39.5 degree Celsius (°C).
Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity.
Grade 3 loss of appetite was defined as the subject not eating at all.
"Any" is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.
|
During the 4-day (Days 0-3) post-booster vaccination period
|
Number of Subjects Reporting Any and Grade 3 Symptoms (Solicited and Unsolicited) - Booster Period
Time Frame: During the 31-day (Days 0-30) post-booster vaccination period
|
The number of subjects with any and grade 3 symptoms (solicited and unsolicited), during the 31-day post-booster vaccination period is reported.
|
During the 31-day (Days 0-30) post-booster vaccination period
|
Number of Subjects With Unsolicited AEs - Primary Period
Time Frame: During the 31-day (Days 0-30) post-primary vaccination period
|
An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
"Any" is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.
|
During the 31-day (Days 0-30) post-primary vaccination period
|
Number of Subjects With Unsolicited AEs - Booster Period
Time Frame: During the 31-day (Days 0-30) post-booster vaccination period
|
An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
"Any" is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.
|
During the 31-day (Days 0-30) post-booster vaccination period
|
Number of Subjects With Serious Adverse Events (SAEs)
Time Frame: From first vaccination (Month 0) up to study end (11-14 months)
|
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
From first vaccination (Month 0) up to study end (11-14 months)
|
Antibody Concentrations Against Pneumococcal Serotypes
Time Frame: At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)
|
Antibodies assessed for this outcome measure were those against the vaccine/cross-reactive pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (ANTI-1, -3, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F).
Antibody concentrations were measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL).
The cut-off of the assay was an antibody concentration higher than or equal to (≥) 0.05 µg/mL.
|
At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)
|
Concentrations of Antibodies Against Protein D (Anti-PD)
Time Frame: At study Month 3 (one month after primary vaccination) and at study Month 11 (one month after booster vaccination)
|
Anti-PD antibody concentrations were measured by Enzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in ELISA Units per milliliter (EL.U/mL).
The cut-off of the assay was an anti-PD antibody concentration higher than or equal to (≥) 153 EL.U/mL.
|
At study Month 3 (one month after primary vaccination) and at study Month 11 (one month after booster vaccination)
|
Titers for Opsonophagocytic Activity Against Pneumococcal Serotypes
Time Frame: At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)
|
The immunogenicity assessment was based on multiplex opsonophagocytic activity assay (MOPA).
Titers for opsonophagocytic activity assessed for this outcome measure were those for opsonophagocytic activity against pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (OPA-1, -3, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F).
The cut-off of the assay was a serotype specific titer for opsonophagocytic activity higher than or equal to (≥) the Lower Limit of Quantification (LLOQ) i.e.: 14 for OPA-1, 11 for OPA-3; 40 for OPA-4; 15 for OPA-5; 45 for OPA-6A; 29 for OPA-6B; 28 for OPA-7F; 39 for OPA-9V; 16 for OPA-14; 40 for OPA-18C; 13 for OPA-19A; 33 for OPA-19F and 40 for OPA-23F.
|
At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 4, 2012
Primary Completion (Actual)
July 15, 2013
Study Completion (Actual)
May 7, 2014
Study Registration Dates
First Submitted
July 12, 2012
First Submitted That Met QC Criteria
July 12, 2012
First Posted (Estimate)
July 16, 2012
Study Record Updates
Last Update Posted (Actual)
March 2, 2021
Last Update Submitted That Met QC Criteria
February 8, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Pneumonia, Bacterial
- Pneumococcal Infections
- Pneumonia, Pneumococcal
- Streptococcal Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- 115992
- 2013-003479-36 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
IPD for this study is available via the Clinical Study Data Request site.
IPD Sharing Time Frame
IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Streptococcus Pneumoniae Vaccines
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae VaccinesSweden
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalMexico
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalVietnam
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalGermany
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalPoland
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalSpain, Greece
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalRussian Federation, Poland
-
Universidad de la SabanaRecruitingCommunity-acquired Pneumonia | Streptococcus Pneumoniae Infection | Streptococcus Pneumoniae Pneumonia | Streptococcus Pneumoniae Infection InvasiveColombia
-
PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedStreptococcus Pneumoniae InfectionsChina
Clinical Trials on Synflorix (3-Dose)
-
Loyola UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Autoimmune Technologies, LLCCompleted
-
Galapagos NVCompletedCystic FibrosisUnited Kingdom, Australia, Ireland, Germany, Czech Republic
-
Aronora, Inc.Completed
-
Medigene AGWithdrawnAcute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia | Malignant LymphomaNetherlands
-
ObsEva SACompletedInfertilityPoland, United Kingdom, Spain, Belgium, Denmark, Czechia
-
Eisai Inc.CompletedHealthy | Drug AbuseCanada
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalRussian Federation, Poland
-
GlaxoSmithKlineTerminatedInfections, StreptococcalPhilippines
-
Innovent Biologics (Suzhou) Co. Ltd.Completed